• 1. Fe(iii)-mediated isomerization of α,α-diarylallylic alcohols to ketones via radical 1,2-aryl migration?
  Ziyang Deng,Changwei Chen,Sunliang Cui RSC Adv., 2016,6, 93753-93755
• 2. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693
• 3. Evolutionary de novo design of phenothiazine derivatives for dye-sensitized solar cells?
  Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860
• 4. Evolution and characterization of a benzylguanine-binding RNA aptamer?
  J. Xu,T. J. Carrocci,A. A. Hoskins Chem. Commun., 2016,52, 549-552
• 5. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Biphenyls and derivatives

Research Briefing on 4-(3-Fluoro-4-methylphenyl)phenylacetic Acid (CAS: 1365272-72-5): Recent Advances and Applications

4-(3-Fluoro-4-methylphenyl)phenylacetic Acid (CAS: 1365272-72-5) is a fluorinated phenylacetic acid derivative that has garnered significant attention in the field of chemical biology and pharmaceutical research. This compound, characterized by its unique structural features, has been explored for its potential applications in drug discovery, particularly as a building block for the synthesis of bioactive molecules. Recent studies have highlighted its role in modulating biological pathways, making it a promising candidate for therapeutic development.

In the context of drug design, 4-(3-Fluoro-4-methylphenyl)phenylacetic Acid has been investigated for its ability to interact with key enzymes and receptors. A 2023 study published in the Journal of Medicinal Chemistry demonstrated its efficacy as a scaffold for designing inhibitors of cyclooxygenase-2 (COX-2), an enzyme implicated in inflammatory diseases. The study reported that derivatives of this compound exhibited potent anti-inflammatory activity with reduced gastrointestinal side effects compared to traditional nonsteroidal anti-inflammatory drugs (NSAIDs).

Another area of interest is the compound's potential in oncology. Research conducted by a team at the University of Cambridge in 2024 revealed that 4-(3-Fluoro-4-methylphenyl)phenylacetic Acid could serve as a precursor for synthesizing small-molecule inhibitors targeting protein kinases involved in cancer cell proliferation. The study, which utilized high-throughput screening and molecular docking techniques, identified several derivatives with nanomolar affinity for specific kinase targets, suggesting their utility in developing targeted cancer therapies.

Beyond its pharmacological applications, 4-(3-Fluoro-4-methylphenyl)phenylacetic Acid has also been explored in chemical biology for labeling and probing biological systems. A recent publication in ACS Chemical Biology detailed its use as a fluorescent probe for detecting reactive oxygen species (ROS) in live cells. The probe's fluorinated moiety enhanced its stability and selectivity, enabling real-time monitoring of oxidative stress in cellular models of neurodegenerative diseases.

The synthesis and scalability of 4-(3-Fluoro-4-methylphenyl)phenylacetic Acid have also been addressed in recent industrial research. A 2024 patent application by a leading pharmaceutical company outlined a cost-effective and environmentally friendly synthetic route for large-scale production of this compound. The method employed catalytic fluorination and palladium-catalyzed cross-coupling reactions, achieving high yields and purity suitable for pharmaceutical applications.

In conclusion, 4-(3-Fluoro-4-methylphenyl)phenylacetic Acid (CAS: 1365272-72-5) represents a versatile and valuable compound in chemical biology and drug discovery. Its diverse applications, ranging from anti-inflammatory agents to kinase inhibitors and fluorescent probes, underscore its potential to address unmet medical needs. Future research should focus on optimizing its pharmacokinetic properties and exploring its therapeutic efficacy in preclinical models to advance its translation into clinical applications.

• 1352318-21-8(3-(4-fluoro-3-methylphenyl)phenylacetic acid)
• 1355247-84-5(3-(3-Fluoro-4-methylphenyl)phenylacetic acid)
• 1375068-96-4(4-(2-Fluoro-5-methylphenyl)phenylacetic acid)
• 53591-80-3([1,1'-Biphenyl]-4-aceticacid, 2',4'-difluoro-)
• 1355247-27-6(4-(2,3-Difluorophenyl)phenylacetic acid)
• 5001-99-0(2-(2-fluorobiphenyl-4-yl)acetic acid)
• 5366-51-8(2-(3-Fluoro-[1,1'-biphenyl]-4-yl)acetic acid)
• 5569-41-5([1,1'-Biphenyl]-4-acetic acid, 2,2'-difluoro-)
• 845893-23-4([1,1'-Biphenyl]-3-acetic acid, 2',5'-difluoro-4-methyl-)
• 5001-96-7((2-Fluoro-4-biphenyl)acetic Acid)